Ruturaj R. Masvekar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ruturaj R. Masvekar has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Bibiana Bielekova
Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
2 shared publications - Ahmed Abdelhak
Department of Neurology and Weill Institute for Neurosciences University of California San Francisco CA USA
1 shared publication - Alessandra Mandelli
Clinical Neuroimmunology Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS Ospedale San Raffaele, and Vita e Salute San Raffaele University , Milan 20132
1 shared publication - Aliyah H. Remoroza1 shared publication
- Anne Hege Aamodt
Department of Neurology, Oslo University Hospital, Norway (A.H.A.).
1 shared publication - Anne Ma Dyrhol-Riise
Department of Infectious Diseases, Oslo University Hospital, Norway
1 shared publication
Latest Publications
- Open Access
- 26 February 2026
- Published by Elsevier in SSRN Electronic Journal
Analytical Evaluation of SARS CoV 2 Spike Protein Stability across Routine Aliquoting and Freezing Methods
Serological assays are essential for infectious disease surveillance and vaccine evaluation because they detect antibody responses that persist beyond the period of active viral replication. The reliability of these assays, however, depends heavily on the structural and functional stability of the antigens used. Recombinant proteins—such as the SARS‑CoV‑2 Spike—are vulnerable to degradation from suboptimal handling, storage, and repeated freeze–thaw cycles, which can compromise assay performance. To address this concern, we systematically assessed the impact of three commonly used aliquoting and freezing approaches on the long‑term stability of a recombinant SARS‑CoV‑2 Spike protein: (1) aliquoting on wet ice followed by storage at −80 °C, (2) aliquoting on dry ice followed by storage at −80 °C, and (3) aliquoting on dry ice followed by snap‑freezing in a methanol–dry ice bath. Aliquots from two manufacturing lots were evaluated over six months using multiple quality metrics, including purity, structural integrity [Analytical Size Exclusion Chromatography (AnSEC) and Thermal Shift Assay (TSA)], and functional performance in a validated IgG ELISA. Across all conditions and time points, antigen purity remained within the ideal A260/A280 range (0.6–0.8), with minimal nucleic acid contamination. ELISA performance demonstrated consistently low background and high sensitivity, specificity, and precision. Structural analyses confirmed stable protein size and conformation (AnSEC elution peaks within ±1.0 mL of baseline) and unchanged thermal stability (Tm within ±2.0 °C). These findings indicate that all tested methodologies effectively preserved antigen integrity under controlled laboratory conditions, providing a foundation for standardized SOPs while acknowledging that real‑world variability may influence outcomes.
- 26 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAnalytical Evaluation of SARS CoV 2 Spike Protein Stability across Routine Aliquoting and Freezing Methods
Serological assays are essential for infectious disease surveillance and vaccine evaluation because they detect antibody responses that persist beyond the period of active viral replication. The reliability of these assays, however, depends heavily on the structural and functional stability of the antigens used. Recombinant proteins—such as the SARS‑CoV‑2 Spike—are vulnerable to degradation from suboptimal handling, storage, and repeated freeze–thaw cycles, which can compromise assay performance. To address this concern, we systematically assessed the impact of three commonly used aliquoting and freezing approaches on the long‑term stability of a recombinant SARS‑CoV‑2 Spike protein: (1) aliquoting on wet ice followed by storage at −80 °C, (2) aliquoting on dry ice followed by storage at −80 °C, and (3) aliquoting on dry ice followed by snap‑freezing in a methanol–dry ice bath. Aliquots from two manufacturing lots were evaluated over six months using multiple quality metrics, including purity, structural integrity [Analytical Size Exclusion Chromatography (AnSEC) and Thermal Shift Assay (TSA)], and functional performance in a validated IgG ELISA. Across all conditions and time points, antigen purity remained within the ideal A260/A280 range (0.6–0.8), with minimal nucleic acid contamination. ELISA performance demonstrated consistently low background and high sensitivity, specificity, and precision. Structural analyses confirmed stable protein size and conformation (AnSEC elution peaks within ±1.0 mL of baseline) and unchanged thermal stability (Tm within ±2.0 °C). These findings indicate that all tested methodologies effectively preserved antigen integrity under controlled laboratory conditions, providing a foundation for standardized SOPs while acknowledging that real‑world variability may influence outcomes.
- Open Access
- 15 May 2023
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (7) , 3315-3328
Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis
Background and aims To investigate the prognostic value of blood neurofilament light chain protein (NfL) levels in the acute phase of coronavirus disease 2019 (COVID-19). Methods We conducted an individual participant data (IPD) meta-analysis after screening on MEDLINE and Scopus to May 23rd 2022. We included studies with hospitalized adult COVID-19 patients without major COVID-19-associated central nervous system (CNS) manifestations and with a measurement of blood NfL in the acute phase as well as data regarding at least one clinical outcome including intensive care unit (ICU) admission, need of mechanical ventilation (MV) and death. We derived the age-adjusted measures NfL Z scores and conducted mixed-effects modelling to test associations between NfL Z scores and other variables, encompassing clinical outcomes. Summary receiver operating characteristic curves (SROCs) were used to calculate the area under the curve (AUC) for blood NfL. Results We identified 382 records, of which 7 studies were included with a total of 669 hospitalized COVID-19 cases (mean age 66.2 ± 15.0 years, 68.1% males). Median NfL Z score at admission was elevated compared to the age-corrected reference population (2.37, IQR: 1.13–3.06, referring to 99th percentile in healthy controls). NfL Z scores were significantly associated with disease duration and severity. Higher NfL Z scores were associated with a higher likelihood of ICU admission, need of MV, and death. SROCs revealed AUCs of 0.74, 0.80 and 0.71 for mortality, need of MV and ICU admission, respectively. Conclusions Blood NfL levels were elevated in the acute phase of COVID-19 patients without major CNS manifestations and associated with clinical severity and poor outcome. The marker might ameliorate the performance of prognostic multivariable algorithms in COVID-19.
- 15 May 2023
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (7) , 3315-3328
Open AccessPrognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis
Background and aims To investigate the prognostic value of blood neurofilament light chain protein (NfL) levels in the acute phase of coronavirus disease 2019 (COVID-19). Methods We conducted an individual participant data (IPD) meta-analysis after screening on MEDLINE and Scopus to May 23rd 2022. We included studies with hospitalized adult COVID-19 patients without major COVID-19-associated central nervous system (CNS) manifestations and with a measurement of blood NfL in the acute phase as well as data regarding at least one clinical outcome including intensive care unit (ICU) admission, need of mechanical ventilation (MV) and death. We derived the age-adjusted measures NfL Z scores and conducted mixed-effects modelling to test associations between NfL Z scores and other variables, encompassing clinical outcomes. Summary receiver operating characteristic curves (SROCs) were used to calculate the area under the curve (AUC) for blood NfL. Results We identified 382 records, of which 7 studies were included with a total of 669 hospitalized COVID-19 cases (mean age 66.2 ± 15.0 years, 68.1% males). Median NfL Z score at admission was elevated compared to the age-corrected reference population (2.37, IQR: 1.13–3.06, referring to 99th percentile in healthy controls). NfL Z scores were significantly associated with disease duration and severity. Higher NfL Z scores were associated with a higher likelihood of ICU admission, need of MV, and death. SROCs revealed AUCs of 0.74, 0.80 and 0.71 for mortality, need of MV and ICU admission, respectively. Conclusions Blood NfL levels were elevated in the acute phase of COVID-19 patients without major CNS manifestations and associated with clinical severity and poor outcome. The marker might ameliorate the performance of prognostic multivariable algorithms in COVID-19.
- Open Access
- 30 March 2021
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 15
Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity
Multiple sclerosis (MS)-related inflammation can be divided into lesional activity, mediated by immune cells migrating from the periphery to the central nervous system (CNS) and non-lesional activity, mediated by inflammation compartmentalized to CNS tissue. Lesional inflammatory activity, reflected by contrast-enhancing lesions (CELs) on the magnetic resonance imaging (MRI), is effectively inhibited by current disease modifying therapies (DMTs). While, the effect of DMTs on non-lesional inflammatory activity is currently unknown. Reliable and simultaneous measurements of both lesional and non-lesional MS activity is necessary to understand their contribution to CNS tissue destruction in individual patients. We previously demonstrated that CNS compartmentalized inflammation can be measured by combined quantification of cerebrospinal fluid (CSF) immune cells and cell-specific soluble markers. The goal of this study is to develop and validate a CSF-biomarker-based molecular surrogate of MS lesional activity. The training cohort was dichotomized into active (CELs > 1 or clinical relapse) and inactive lesional activity (no CELs or relapse) groups. Matched CSF and serum samples were analyzed for 20 inflammatory and axonal damage biomarkers in a blinded fashion. Only the findings from the training cohort with less than 0.1% probability of false positive (i.e.,p< 0.001) were validated in an independent validation cohort. MS patients with lesional activity have elevated IL-12p40, CHI3L1, TNFα, TNFβ, and IL-10, with the first two having the strongest effects and validated statistically-significant association with lesional activity in an independent validation cohort. Marker of axonal damage, neurofilament light (NfL), measured in CSF (cNfL) was also significantly elevated in MS patients with active lesions. NfL measured in serum (sNfL) did not differentiate the two MS subgroups with pre-determined significance, (p= 0.0690) even though cCSF and sNfL correlated (Rho = 0.66,p< 0.0001). Finally, the additive model of IL12p40 and CHI3L1 outperforms any biomarker discretely. IL12p40 and CHI3L1, released predominantly by immune cells of myeloid lineage are reproducibly the best CSF biomarkers of MS lesional activity. The residuals from the IL12p40/CHI3L1-cNfL correlations may identify MS patients with more destructive inflammation or contributing neurodegeneration.
- 30 March 2021
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 15
Open AccessCerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity
Multiple sclerosis (MS)-related inflammation can be divided into lesional activity, mediated by immune cells migrating from the periphery to the central nervous system (CNS) and non-lesional activity, mediated by inflammation compartmentalized to CNS tissue. Lesional inflammatory activity, reflected by contrast-enhancing lesions (CELs) on the magnetic resonance imaging (MRI), is effectively inhibited by current disease modifying therapies (DMTs). While, the effect of DMTs on non-lesional inflammatory activity is currently unknown. Reliable and simultaneous measurements of both lesional and non-lesional MS activity is necessary to understand their contribution to CNS tissue destruction in individual patients. We previously demonstrated that CNS compartmentalized inflammation can be measured by combined quantification of cerebrospinal fluid (CSF) immune cells and cell-specific soluble markers. The goal of this study is to develop and validate a CSF-biomarker-based molecular surrogate of MS lesional activity. The training cohort was dichotomized into active (CELs > 1 or clinical relapse) and inactive lesional activity (no CELs or relapse) groups. Matched CSF and serum samples were analyzed for 20 inflammatory and axonal damage biomarkers in a blinded fashion. Only the findings from the training cohort with less than 0.1% probability of false positive (i.e.,p< 0.001) were validated in an independent validation cohort. MS patients with lesional activity have elevated IL-12p40, CHI3L1, TNFα, TNFβ, and IL-10, with the first two having the strongest effects and validated statistically-significant association with lesional activity in an independent validation cohort. Marker of axonal damage, neurofilament light (NfL), measured in CSF (cNfL) was also significantly elevated in MS patients with active lesions. NfL measured in serum (sNfL) did not differentiate the two MS subgroups with pre-determined significance, (p= 0.0690) even though cCSF and sNfL correlated (Rho = 0.66,p< 0.0001). Finally, the additive model of IL12p40 and CHI3L1 outperforms any biomarker discretely. IL12p40 and CHI3L1, released predominantly by immune cells of myeloid lineage are reproducibly the best CSF biomarkers of MS lesional activity. The residuals from the IL12p40/CHI3L1-cNfL correlations may identify MS patients with more destructive inflammation or contributing neurodegeneration.
- Open Access
- 17 March 2015
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 13 (1) , 10-20
Chronic HIV-1 Tat and HIV Reduce Rbfox3/NeuN: Evidence for Sex- Related Effects
The NeuN antibody has been widely used to identify and quantify neurons in normal and disease situations based on binding to a nuclear epitope in most types of neurons. This epitope was recently identified as the RNA-binding, feminizing locus on X-3 (Rbfox3), a member of the larger, mammalian Fox1 family of RNA binding proteins. Fox1 proteins recognize a unique UGCAUG mRNA motif and regulate alternative splicing of precursor mRNA to control post-transcriptional events important in neuronal differentiation and central nervous system development. Recent clinical findings show that Rbfox3/NeuN gene dosage is altered in certain human neurodevelopmental disorders, and redistribution has been noted in HIV+ tissue. We hypothesized that HIV-1 Tat might affect Rbfox3/NeuN expression, and examined this question in vivo using inducible transgenic mice, and in vitro using human mesencephalic-derived neurons. Rbfox3/NeuN expression and localization in HIV+ basal ganglia and hippocampus was also examined. Chronic Tat exposure reduced Rbfox3/NeuN protein levels and increased cytoplasmic localization, similar to the effect of HIV exposure. Cytoplasmic Rbfox3/NeuN signal has occasionally been reported, although the meaning or function of cytoplasmic versus nuclear localization remains speculative. Importantly, Rbfox3/NeuN reductions were more significant in male mice. Although Rbfox3/NeuN-expressing cells were significantly decreased by Tat exposure, stereology showed that Nissl+ neuron numbers remained normal. Thus, loss of Rbfox3/NeuN may relate more to functional change than to neuron loss. The effects of Tat by itself are highly relevant to HIV+ individuals maintained on antiretroviral therapy, since Tat is released from infected cells even when viral replication is inhibited.
- 17 March 2015
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 13 (1) , 10-20
Open AccessChronic HIV-1 Tat and HIV Reduce Rbfox3/NeuN: Evidence for Sex- Related Effects
The NeuN antibody has been widely used to identify and quantify neurons in normal and disease situations based on binding to a nuclear epitope in most types of neurons. This epitope was recently identified as the RNA-binding, feminizing locus on X-3 (Rbfox3), a member of the larger, mammalian Fox1 family of RNA binding proteins. Fox1 proteins recognize a unique UGCAUG mRNA motif and regulate alternative splicing of precursor mRNA to control post-transcriptional events important in neuronal differentiation and central nervous system development. Recent clinical findings show that Rbfox3/NeuN gene dosage is altered in certain human neurodevelopmental disorders, and redistribution has been noted in HIV+ tissue. We hypothesized that HIV-1 Tat might affect Rbfox3/NeuN expression, and examined this question in vivo using inducible transgenic mice, and in vitro using human mesencephalic-derived neurons. Rbfox3/NeuN expression and localization in HIV+ basal ganglia and hippocampus was also examined. Chronic Tat exposure reduced Rbfox3/NeuN protein levels and increased cytoplasmic localization, similar to the effect of HIV exposure. Cytoplasmic Rbfox3/NeuN signal has occasionally been reported, although the meaning or function of cytoplasmic versus nuclear localization remains speculative. Importantly, Rbfox3/NeuN reductions were more significant in male mice. Although Rbfox3/NeuN-expressing cells were significantly decreased by Tat exposure, stereology showed that Nissl+ neuron numbers remained normal. Thus, loss of Rbfox3/NeuN may relate more to functional change than to neuron loss. The effects of Tat by itself are highly relevant to HIV+ individuals maintained on antiretroviral therapy, since Tat is released from infected cells even when viral replication is inhibited.